246 related articles for article (PubMed ID: 27088490)
21. A Prospective Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel for Borderline Resectable Pancreatic Cancer with Arterial Involvement.
Ikenaga N; Miyasaka Y; Ohtsuka T; Nakata K; Adachi T; Eguchi S; Nishihara K; Inomata M; Kurahara H; Hisaka T; Baba H; Nagano H; Ueki T; Noshiro H; Tokunaga S; Ishigami K; Nakamura M;
Ann Surg Oncol; 2023 Jan; 30(1):193-202. PubMed ID: 36207481
[TBL] [Abstract][Full Text] [Related]
22. Neoadjuvant Chemotherapy with Gemcitabine Plus Nab-Paclitaxel Regimen for Borderline Resectable Pancreatic Cancer with Arterial Involvement: A Prospective Multicenter Single-Arm Phase II Study Protocol.
Miyasaka Y; Ohtsuka T; Eguchi S; Inomata M; Nishihara K; Shinchi H; Okuda K; Baba H; Nagano H; Ueki T; Noshiro H; Nakamura M;
Int J Surg Protoc; 2021 Apr; 25(1):55-60. PubMed ID: 34013145
[TBL] [Abstract][Full Text] [Related]
23. Endoscopic ultrasonography complements computed tomography in predicting portal or superior mesenteric vein resection in patients with borderline resectable pancreatic carcinoma.
Glazer ES; Rashid OM; Klapman JB; Harris CL; Hodul PJ; Pimiento JM; Malafa MP
Pancreatology; 2017; 17(1):130-134. PubMed ID: 28043760
[TBL] [Abstract][Full Text] [Related]
24. Peptide receptor radionuclide therapy as neoadjuvant therapy for resectable or potentially resectable pancreatic neuroendocrine neoplasms.
Partelli S; Bertani E; Bartolomei M; Perali C; Muffatti F; Grana CM; Schiavo Lena M; Doglioni C; Crippa S; Fazio N; Zamboni G; Falconi M
Surgery; 2018 Apr; 163(4):761-767. PubMed ID: 29284590
[TBL] [Abstract][Full Text] [Related]
25. Neoadjuvant therapy offers longer survival than upfront surgery for poorly differentiated and higher stage pancreatic cancer.
Nurmi A; Mustonen H; Parviainen H; Peltola K; Haglund C; Seppänen H
Acta Oncol; 2018 Jun; 57(6):799-806. PubMed ID: 29241394
[TBL] [Abstract][Full Text] [Related]
26. Favorable perioperative outcomes after resection of borderline resectable pancreatic cancer treated with neoadjuvant stereotactic radiation and chemotherapy compared with upfront pancreatectomy for resectable cancer.
Mellon EA; Strom TJ; Hoffe SE; Frakes JM; Springett GM; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
J Gastrointest Oncol; 2016 Aug; 7(4):547-55. PubMed ID: 27563444
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant S-1 with concurrent radiotherapy followed by surgery for borderline resectable pancreatic cancer: study protocol for an open-label, multicentre, prospective phase II trial (JASPAC05).
Takahashi S; Ohno I; Ikeda M; Kobayashi T; Akimoto T; Kojima M; Konishi M; Uesaka K
BMJ Open; 2017 Oct; 7(10):e018445. PubMed ID: 29061632
[TBL] [Abstract][Full Text] [Related]
28. Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis.
Pan L; Fang J; Tong C; Chen M; Zhang B; Juengpanich S; Wang Y; Cai X
World J Surg Oncol; 2019 Dec; 18(1):1. PubMed ID: 31892339
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy Enhances Local Postoperative Histopathological Tumour Stage in Borderline Resectable Pancreatic Cancer - A Matched-Pair Analysis.
Timmermann L; Rosumeck N; Klein F; Pratschke J; Pelzer U; Bahra M; Malinka T
Anticancer Res; 2019 Oct; 39(10):5781-5787. PubMed ID: 31570482
[TBL] [Abstract][Full Text] [Related]
30. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
[TBL] [Abstract][Full Text] [Related]
31. Relationship between surgical R0 resectability and findings of peripancreatic vascular invasion on CT imaging after neoadjuvant S-1 and concurrent radiotherapy in patients with borderline resectable pancreatic cancer.
Yasuta S; Kobayashi T; Aizawa H; Takahashi S; Ikeda M; Konishi M; Kojima M; Kuno H; Uesaka K; Morinaga S; Miyamoto A; Toyama H; Takakura N; Sugimachi K; Takayama W
BMC Cancer; 2020 Dec; 20(1):1184. PubMed ID: 33267820
[TBL] [Abstract][Full Text] [Related]
32. Comparison the efficacy and safety of different neoadjuvant regimens for resectable and borderline resectable pancreatic cancer: a systematic review and network meta-analysis.
Li X; Huang J; Jiang C; Chen P; Quan Q; Jiang Q; Li S; Guo G
Eur J Clin Pharmacol; 2023 Mar; 79(3):323-340. PubMed ID: 36576528
[TBL] [Abstract][Full Text] [Related]
33. Current update of treatment strategies for borderline resectable pancreatic cancer: a narrative review.
Ono A; Murakami Y; Abdel-Wahab M; Nagata Y
J Gastrointest Oncol; 2022 Apr; 13(2):885-897. PubMed ID: 35557564
[TBL] [Abstract][Full Text] [Related]
34. TRIANGLE operation for borderline resectable pancreatic cancer in total pancreatectomy.
Zhai S; Huo Z; Wang Y; Qian H; Zhao S; Shi Y; Weng Y; Deng X; Shen B
Transl Cancer Res; 2019 Oct; 8(6):2416-2424. PubMed ID: 35116994
[TBL] [Abstract][Full Text] [Related]
35. Multimodality management of borderline resectable pancreatic adenocarcinoma.
Prakash LR; Katz MHG
Chin Clin Oncol; 2017 Jun; 6(3):27. PubMed ID: 28705004
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of neoadjuvant FOLFIRINOX for borderline resectable pancreatic adenocarcinoma: improved efficacy compared with gemcitabine-based regimen.
Yoo C; Kang J; Kim KP; Lee JL; Ryoo BY; Chang HM; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Hwang DW; Song KB; Lee JH; Kim SC
Oncotarget; 2017 Jul; 8(28):46337-46347. PubMed ID: 28564637
[TBL] [Abstract][Full Text] [Related]
37. Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy.
Mellon EA; Jin WH; Frakes JM; Centeno BA; Strom TJ; Springett GM; Malafa MP; Shridhar R; Hodul PJ; Hoffe SE
Acta Oncol; 2017 Mar; 56(3):391-397. PubMed ID: 27885876
[TBL] [Abstract][Full Text] [Related]
38. Preoperative ultrasound ablation for borderline resectable pancreatic cancer: A report of 30 cases.
Wang G; Zhou D
Ultrason Sonochem; 2015 Nov; 27():694-702. PubMed ID: 26113389
[TBL] [Abstract][Full Text] [Related]
39. [Analysis on the clinical therapeutic effects of arterial first approach pancreatoduodenectomy in the treatment of borderline resectable pancreatic adenocarcinoma].
Jin G; Zheng KL; Guo SW; Shao Z; Liu C; Shi XH; Liu RD; Bai SJ; Jiang H; Bian Y; Hu XG
Zhonghua Wai Ke Za Zhi; 2017 Dec; 55(12):909-915. PubMed ID: 29224265
[No Abstract] [Full Text] [Related]
40. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
